Key result
Swedish moist snuff use was not associated with excess mortality or hospitalization from IHD or stroke.
Cohort
Answers are grounded in this paper and cite their sources.
BACKGROUND: The potential risks of Swedish moist snuff (snus) are debated and studies have shown diverging results. AIMS: The aim of this study is to investigate whether there is any excess risk of ischaemic heart disease (IHD) and stroke from snuff use. METHODS: The Swedish Survey of Living Conditions from 1988-89 was record-linked to the Swedish Cause of Death Register and the Swedish Hospital Discharge Register to investigate excess mortality and hospitalization from IHD and stroke. A Poisson regression model was used and incidence rate ratios (IRRs) for snuff and smoking were calculated controlling for age, physical activity, self-reported health, number of longstanding illnesses, residential area, and socioeconomic position. RESULTS: Among snuff users there were no excess risks of mortality or hospitalization from IHD (IRR 0.8; 0.5-1.2,) or stroke (IRR 1.1; 0.7-1.8), but, as expected, clear excess risks were found for smokers (IRR 1.7; 1.4-2.1 for IHD, and IRR 1.4; 1.0-1.9 for stroke). CONCLUSIONS: This study has not shown any excess risk among users of snuff for IHD or stroke. If there is a risk associated with snuff it is evidently much lower than those associated with smoking.
No takes yet. Share an insight, caveat, or question.
Haglund et al. (2007) conducted a cohort in Ischaemic heart disease (IHD) and stroke. Swedish moist snuff (snus) use vs. Non-users and smokers was evaluated on Mortality or hospitalization from ischaemic heart disease (IHD) and stroke (IRR 0.8 (IHD); IRR 1.1 (stroke), 95% CI 0.5-1.2). Swedish moist snuff use was not associated with excess mortality or hospitalization from IHD or stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: